China pledges efforts to fight healthcare bribery

 GSK is currently under investigation in China for suspected bribery and tax-related offenses.

GSK is currently under investigation in China for suspected bribery and tax-related offenses.

China’s National Health and Family Planning Commission vowed to continue working with judicial agencies in efforts to curb commercial bribery in the pharmaceutical industry and health service sector.   The Commission’s latest target is British pharmaceutical giant GlaxoSmithKline (GSK), which has been under investigation for suspected bribery and tax-related offenses since early July.

In addition to investigating and punishing parties that give and receive bribes, the Commission also plans to blacklist pharmaceutical companies and individuals (salespeople and doctors) involved in bribery.

One Response to “China pledges efforts to fight healthcare bribery”

  1. Ethan soderlund
    2014年4月14日 at 上午10:18 #

    UK drug company GSK ‘paid bribes to Polish doctors’:

    The Lodz public prosecutor found evidence in documents given to doctors by GSK to support claims of corrupt payments in more than a dozen different health centres where there was no evidence “patient education” had taken place.

评论